Drug Trial Radar · NCT04000529
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
122
Actual
Start
Jul 30, 2019
Primary completion
Jan 15, 2024
Study completion Jan 15, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.
Conditions
- Non-small Cell Lung Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Esophageal SCC
- Gastrointestinal Stromal Tumors
- Colorectal Cancer
Interventions
TNO155Drug
Capsule
SpartalizumabDrug
Concentrate for solution for infusion
RibociclibDrug
Capsule and tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT incidenceTime frame: 1 year
- AE and SAE incidenceTime frame: 3 years
- Dose interruptions, reductions and dose intensity, by treatmentTime frame: 3 years
Locations
10 sites in 9 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Chengdu, Sichuan, China
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.